• Home
• Contact Us
• English | Français

• Corporate
  • Corporate Profile
  • Management Team
  • Board of Directors
  • Charter
  • Mandate of the Audit Committee
  • Code of Ethics
  • Careers at ConjuChem
  • Contact Us
• Technology
  • Technology platforms
  • About DAC™
  • About PC-DAC™
  • DAC™ Animation
• Products
  • PC-DAC™:Exendin-4
  • PC-DAC™:Insulin
  • DAC™:HIV
• Partnering
• Investors
  • Company Overview
  • Challenges
  • Business of ConjuChem
  • Benefits of Technology
  • Shareholder Value
  • Financial Information
  • Press Releases
• Careers
• Glossary

Investors

• Company Overview
• Challenges
• Business of ConjuChem
• Benefits of Technology
• Shareholder Value
• Financial Information
• Press Releases

ConjuChem Investor Information

The Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™) technology platforms created by ConjuChem have very broad applicability. The Company has identified and investigated a large number of small organic molecules and therapeutic peptides it believes could be used to form new constructs with attractive market potential.

2007 Annual Report

© 1999-2007, ConjuChem, Inc. All rights reserved.